Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 19/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4923253 | 0.90 | SLC16A1 (0.52) | SLC16A1CYP2C9CYP3A4ABCB11 | |
| SCHEMBL3871428 | 0.89 | SLC16A1 (0.51) | SLC16A1CYP2C9CYP3A4ABCB11 | |
| SCHEMBL4802281 | 0.88 | SLC16A1 (0.64) | SLC16A1CYP2C9CYP3A4ABCB11MEN1 | |
| SCHEMBL4804153 | 0.87 | SLC16A1 (0.56) | SLC16A1CYP2C9CYP3A4ABCB11 | |
| SCHEMBL3833122 | 0.84 | SLC16A1 (0.53) | SLC16A1CYP2C9CYP3A4ABCB11 | |
| SCHEMBL3833615 | 0.83 | SLC16A1 (0.52) | SLC16A1CYP2C9CYP3A4ABCB11 | |
| SCHEMBL5788817 | 0.83 | SLC16A1 (0.49) | SLC16A1CYP2C9CYP3A4ABCB11 | |
| SCHEMBL3827850 | 0.82 | SLC16A1 (0.71) | SLC16A1CYP2C9CYP3A4 | |
| SCHEMBL3827852 | 0.82 | SLC16A1 (0.71) | SLC16A1CYP2C9CYP3A4 | |
| SCHEMBL3833746 | 0.80 | SLC16A1 (0.61) | SLC16A1CYP2C9CYP3A4ABCB11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414825-B9 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2009-09-16 | — | — | EP | disclosed |
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-7384950-B2 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| EP-1414825-B1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | TPMT, CBR1, CYP2D6 | SLC16A1 3284/4885CYP2C9 89/4885CYP3A4 93/4885 |
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | C5, TPMT, C9 | SLC16A1 3369/4885CYP2C9 71/4885CYP3A4 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.